BIOAFFINITY TECHNOLOGIES INC (BIAF)

Company Profile

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 14 full-time employees. The company went IPO on 2022-08-26. The firm is focused on addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as a targeted cancer treatment. The firm develops noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Its lead product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. Through its wholly owned subsidiary, OncoSelect Therapeutics, LLC, the Company’s research is engaged in the discoveries and advancement of cancer therapeutics that specifically and selectively target cancer cells. The company is focused on expanding its platform technologies in developing tests that detect and therapies that target various types of cancer and potentially other diseases.

Company Info

BIOAFFINITY TECHNOLOGIES INC

22211 West Interstate-10, Suite 1206

San Antonio TEXAS

P: 12106985334

Employees: 14

Website: https://bioaffinitytech.com/